Health
New Zealand approves MDMA for severe PTSD treatment
Regulator Medsafe authorizes two psychiatrists to prescribe the psychedelic in clinical settings, making New Zealand the second country to approve the therapy.
The short version
- New Zealand's medicines regulator, Medsafe, approved two psychiatrists to prescribe pharmaceutical-grade MDMA for treating severe PTSD.
- Patients aged 18 and older will receive the drug in supervised clinical environments alongside psychotherapy, with no take-home doses allowed.
- New Zealand follows Australia as the second nation to approve MDMA for PTSD, contrasting with the United States where the FDA rejected medicinal approval in 2024.
Key facts
- Medsafe authorized two psychiatrists to prescribe pharmaceutical-grade MDMA to adults with severe post-traumatic stress disorder.[The Guardian]
- New Zealand is the second country to approve MDMA for medicinal use in PTSD treatment, following Australia's authorization in 2023.[The Guardian]
- According to the Ministry of Health, treatment must occur in a controlled clinical setting with psychotherapy, and patients will not receive take-home prescriptions.[The Guardian]
- Deputy Prime Minister David Seymour publicly endorsed the decision, framing it as part of a commitment to expanding access to innovative medical treatments.[The Guardian]
What remains uncertain
- It remains unknown how widely New Zealand regulators will expand prescribing authorization beyond the initial two approved psychiatrists.[The Guardian]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- New Zealand drugs regulator approves use of MDMA to treat severe PTSDThe Guardian - Science